(MedPage Today) -- In overweight, prediabetic schizophrenia patients on second-generation antipsychotics, semaglutide (Ozempic) significantly improved insulin sensitivity, fasting glucose, and weight. (Diabetes Care)
Experts weighed in on whether...
New research challenges fears about Ozempic weight regain. Cleveland Clinic study of 8,000 patients finds minimal rebound after stopping GLP-1 medications.
Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults now take these medications, which also provide cardiovascular benefits. However, when patients stop taking these drugs, they not only regain weight, but, according to a new study, they also incur increased risk of heart attack, stroke, and death compared to staying on the medication.
New research highlights a need for earlier, more tailored interventions to prevent type 2 diabetes in young adults with prediabetes. Klaus Vedfelt/Getty Images
Researchers found that type 2 diabetes risk varies among adults ages 18 to 40.
Those with high fasting glucose, especially if they qualified for GLP-1 treatment, had higher risk.
Tirzepatide may help lower the risk of diabetic retinopathy, a diabetes complication that can lead to vision loss. Douglas Sacha/Getty Images
Weight loss medications Mounjaro and Zepbound, which contain the active ingredient tirzepatide, may lower the risk of diabetic retinopathy.
People who lose weight with GLP-1 drugs are likely to continue using the medication despite the side effects. Image Credit: geckophotos/Getty Images
A recent study found that many people using GLP-1 drugs for weight loss choose to continue the medication despite unpleasant side effects.
